In addition, with advances in treatments for BC that control systemic metastatic diseases at other organs, such as the monoclonal antibody trastuzumab, new challenges of controlling BCBM have emerged in cases of HER2+ BC21, 22. This evidence concerns the gene ERBB2 and breast cancer.